SCHEMBL20913982

SCHEMBL20913982

COc1c(N)ccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 2/20 0.34
▸ MEN1 O00255 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ADORA2A P29274 2/20 0.31
▸ EGFR P00533 1/20 0.30
▸ PDGFRB P09619 1/20 0.30
▸ FGFR1 P11362 1/20 0.30
▸ FGFR2 P21802 1/20 0.30
▸ FGFR4 P22455 1/20 0.30
▸ FGFR3 P22607 1/20 0.30
▸ KDR P35968 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ ADRA2A P08913 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914018 0.91 MAT2A (0.34) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20837038 0.88 ADORA2A (0.34) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914077 0.86 TNKS (0.37) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20837047 0.85 MAT2A (0.33) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914059 0.85 MAT2A (0.33) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914308 0.85 MAT2A (0.34) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20913968 0.83 KDM4E (0.34) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914035 0.83 MAT2A (0.34) MAT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914318 0.82 RAB9A (0.41) MEN1PKMTSHRKMT2AADORA2A
SCHEMBL20837037 0.81 P2RY6 (0.37) MEN1CYP1A2CYP2C9PKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 MAT2A 1893/4885MEN1 2785/4885CYP1A2 1015/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 MAT2A 1893/4885MEN1 2785/4885CYP1A2 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback